Evidence map›Paper›PMID 33666656›Full record

ArticleBlood advances2021

Impact of event-free survival status after stem cell transplantation on subsequent survival of patients with lymphoma.

Ayumi Fujimoto, Tatsuhiko Anzai, Takahiro Fukuda, Naoyuki Uchida, Takanori Ohta, Takehiko Mori, Masashi Sawa, Satoshi Yoshioka, Toshihiro Miyamoto, Hitoji Uchiyama and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 16 institutions in 1 country.

Ayumi FujimotoDepartment of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.
Tatsuhiko AnzaiDepartment of Biostatistics, M&D Data Science Center, Tokyo Medical Dental University, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan.
Takanori OhtaDepartment of Hematology, Kitakyushu City Hospital Organization, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.
Takehiko MoriDivision of Hematology, Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.
Masashi SawaDepartment of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan.
Satoshi YoshiokaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Toshihiro MiyamotoDepartment of Medicine and Biosystemic Science, Graduate School of Medicine, Kyushu University, Fukuoka, Japan.
Hitoji UchiyamaDepartment of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
Ken-Ichi MatsuokaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Souichi ShiratoriDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Hideyuki NakazawaDepartment of Hematology, School of Medicine, Shinshu University, Nagano, Japan.
Junya KandaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Department of Healthcare Administration, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Naoto FujitaDepartment of Pediatrics, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan; and.
Eisei KondoDepartment of Hematology, Kawasaki Medical School, Okayama, Japan.
Ritsuro SuzukiDepartment of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.
Shimane University Hospital · JPAnjo Kosei Hospital · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPHiroshima University · JPHokkaido University Hospital · JPKawasaki Medical School · JPKeio University · JPKitakyushu Municipal Medical Center · JPKobe City Medical Center General Hospital · JPKyoto first Red Cross hospital · JPKyoto University · JPKyushu University · JPOkayama University Hospital · JPThe Japanese Data Center for Hematopoietic Cell Transplantation · JPTokyo Medical and Dental University · JPToranomon Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the impact of event-free survival (EFS) status at 24 months (EFS24) and 60 months (EFS60) after hematopoietic stem cell transplantation (HSCT) using registry data. Patients who underwent their first autologous HSCT (auto-HSCT) or allogeneic HSCT (allo-HSCT) for lymphoma between 1981 and 2018 were included. Overall survival was compared with that of the age-, sex, and calendar period-matched general population. A total of 14 977 patients, including 10 964 and 4013 who underwent auto-HSCT and allo-HSCT, respectively, were analyzed. Although patients who achieved EFS24 and EFS60 had favorable outcomes, most had significantly poorer survival rates than the general population. The standardized mortality ratios (SMRs) of patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) were significantly higher than that of the general population even after achieving EFS24 or EFS60. The SMRs of those after auto-HSCT were 2.5 to 3.5 and 2.7 to 3.7, respectively. The SMR was consistently highest in Hodgkin lymphoma (HL) patients after HSCT. By contrast, subsequent survival of patients with primary mediastinal large B-cell lymphoma, intravascular large B-cell lymphoma, or peripheral T-cell lymphoma, not otherwise specified, who achieved EFS60 after auto-HSCT, and those with extranodal natural killer/T-cell lymphoma who achieved EFS60 after allo-HSCT did not significantly differ from that of the general population, with SMRs of 1.6, 1.2, 1.8, and 1.3, respectively. Our results suggest that EFS24 and EFS60 were clinically useful end points after HSCT for lymphoma patients. Furthermore, patients with certain lymphoma subtypes who achieved EFS had a comparable prognosis with that of the general population and were potentially cured after HSCT.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseAdultHumansProgression-Free SurvivalStem Cell TransplantationTransplantation, Autologous

Identifiers

PMID33666656
PMCPMC7948259
OpenAlexW3134552657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.